Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Clonazepam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 8/20 | 0.64 |
| ▸ | GABRA5 known ✓ | P31644 | 8/20 | 0.64 |
| ▸ | GABRA3 known ✓ | P34903 | 8/20 | 0.64 |
| ▸ | GABRG2 known ✓ | P18507 | 7/20 | 0.64 |
| ▸ | GABRB3 known ✓ | P28472 | 7/20 | 0.64 |
| ▸ | GABRA2 known ✓ | P47869 | 7/20 | 0.64 |
| ▸ | GABRB2 known ✓ | P47870 | 6/20 | 0.64 |
| ▸ | GABRP known ✓ | O00591 | 4/20 | 0.64 |
| ▸ | GABRD known ✓ | O14764 | 4/20 | 0.64 |
| ▸ | GABRB1 known ✓ | P18505 | 4/20 | 0.64 |
| ▸ | GABRA4 known ✓ | P48169 | 4/20 | 0.64 |
| ▸ | GABRE known ✓ | P78334 | 4/20 | 0.64 |
| ▸ | GABRA6 known ✓ | Q16445 | 4/20 | 0.64 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 4/20 | 0.64 |
| ▸ | GABRG3 known ✓ | Q99928 | 4/20 | 0.64 |
| ▸ | GABRQ known ✓ | Q9UN88 | 4/20 | 0.64 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clonazepam SCHEMBL17728660 | 0.85 | GABRA1 (0.67) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Flunitrazepam SCHEMBL8364961 | 0.82 | GABRA1 (0.64) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Clonazepam SCHEMBL20771795 | 0.80 | GABRA1 (0.96) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Clonazepam SCHEMBL29361251 | 0.80 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Clonazepam SCHEMBL29369721 | 0.80 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Clonazepam SCHEMBL13746712 | 0.80 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Clonazepam SCHEMBL13747803 | 0.80 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Clonazepam SCHEMBL38899 | 0.80 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Clonazepam SCHEMBL29743048 | 0.80 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 | |
| Clonazepam SCHEMBL5501860 | 0.80 | GABRA1 (1.00) | GABRA1GABRA5GABRA3GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12042471-B2 | Ocular treatments for neurological and neuropsychiatric disorders | PHOTOPHARMICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20220110911-A1 | CANNABINOID COMPOSITION AND PROCESSES OF MANUFACTURE | VIALPANDO, LLC (US) | 2022-04-14 | — | — | US | disclosed |
| EP-3962457-A1 | CANNABINOID COMPOSITION AND PROCESSES OF MANUFACTURE | Vialpando, LLC (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2021110085-A1 | METHOD FOR ASSOCIATING WITH EXPRESSION LEVEL OF AKR1C3 ENZYME VIA CONTENT OF PROSTAGLANDIN, AND USE OF SCREENING FOR DRUG ADMINISTRATION | 深圳艾欣达伟医药科技有限公司 | 2021-06-10 | — | — | WO | disclosed |
| WO-2020234675-A1 | AMORPHOUS CANNABINOID COMPOSITION AND PROCESSES OF MANUFACTURE | VIALPANDO, LLC (AU) | 2020-11-26 | — | — | WO | disclosed |
| WO-2020222029-A1 | CANNABINOID COMPOSITION AND PROCESSES OF MANUFACTURE | VIALPANDO, LLC (US) | 2020-11-05 | — | — | WO | disclosed |
| US-20200345684-A1 | CANNABINOID COMPOSITION AND PROCESSES OF MANUFACTURE | VIALPANDO, LLC | 2020-11-05 | — | — | US | disclosed |
| CN-109106699-A | Pharmaceutical composition for treating epilepsy, preparation method and application thereof | 汉义生物科技（北京）有限公司 | 2019-01-01 | — | — | CN | disclosed |
| CN-108785298-A | Pharmaceutical composition for treating epilepsy, preparation method and application thereof | 汉义生物科技（北京）有限公司 | 2018-11-13 | — | — | CN | disclosed |
| US-20180296642-A1 | METHODS FOR TREATING CARDIAC INJURY | MaineHealth | 2018-10-18 | — | — | US | disclosed |
| US-20180140561-A1 | TREATMENT OR PROPHYLAXIS OF A NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION | PHOVITREAL PTY LTD (AU) | 2018-05-24 | — | — | US | disclosed |
| US-9827210-B2 | Treatment or prophylaxis of a neurological or neuropsychiatric disorders via ocular administration | PHOVITREAL PTY LTD (AU) | 2017-11-28 | — | — | US | disclosed |
| EP-2173344-B1 | TREATMENT OR PROPHYLAXIS OR NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION | CLARENCEW PTY LTD (AU) | 2016-04-06 | — | — | EP | disclosed |
| US-20100189698-A1 | TREATMENT OR PROPHYLAXIS OF A NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION | CLARENCEW PTY LTD (AU) | 2010-07-29 | — | — | US | disclosed |
| EP-2173344-A1 | TREATMENT OR PROPHYLAXIS OR NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION | Clarencew Pty Ltd. (AU) | 2010-04-14 | — | — | EP | disclosed |
| WO-2009003226-A1 | TREATMENT OR PROPHYLAXIS OR NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION | CLARENCEW PTY LTD (AU) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12042471-B2 | Ocular treatments for neurological and neuropsychiatric disorders | SLC18A2, SLC6A3, SLC18A3 | GABRA1 151/4885GABRA5 129/4885GABRA3 169/4885 |
| US-20100189698-A1 | TREATMENT OR PROPHYLAXIS OF A NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION | SLC6A3, SLC18A2, SLC6A2 | GABRA1 108/4885GABRA5 89/4885GABRA3 125/4885 |
| US-20180140561-A1 | TREATMENT OR PROPHYLAXIS OF A NEUROLOGICAL OR NEUROPSYCHIATRIC DISORDERS VIA OCULAR ADMINISTRATION | SLC6A3, SLC18A2, SLC6A2 | GABRA1 108/4885GABRA5 89/4885GABRA3 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.